WuXi Biologics Achieves Fourth EMA GMP Certification for Its Biosafety Testing Center in Suzhou

WuXi Biologics' Success in European Market with EMA Certification

WuXi Biologics, a major player in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, has accomplished a significant milestone by securing its fourth Good Manufacturing Practice (GMP) certification from the European Medicines Agency (EMA) for its Biosafety Testing Center located in Suzhou, China. This milestone not only underscores the facility’s robust adherence to stringent regulatory standards but also enables the company to support 19 commercial products tailored for the European market.

The recent inspection, conducted by the EMA, was noteworthy for its lack of any critical findings, highlighting the exemplary standards upheld by WuXi Biologics. This accomplishment facilitates marketing authorization applications for 19 biologics, developed by 13 clients, that encompass a variety of modalities including antibodies, enzymes, and fusion proteins. The focus during the inspection revolved around the biosafety quality control testing of vital components such as cell banks and commercial unprocessed bulk.

The significance of GMP compliance in biosafety testing cannot be overstated. It is a crucial aspect of pre-licensure evaluations for biologics aiming for approval in the European Union. Therefore, maintaining rigorous inspection and testing protocols is essential not only for regulatory compliance but also for ensuring the safety and efficacy of the products being manufactured.

During the comprehensive four-day inspection, the EMA evaluated several critical areas, including quality management systems, the integrity and capability of facilities and equipment, testing methodologies, standard operating procedures, and overall personnel management. WuXi Biologics' facility in Suzhou showcased high standards in quality systems, technical capabilities, and data integrity, which greatly impressed the EMA inspectors. This recognition is a testament to WuXi Biologics' commitment to excellence and reliability in biologics manufacturing.

Dr. Chris Chen, the CEO of WuXi Biologics, emphasized the importance of biosafety testing throughout the biologics lifecycle. He stated that the testing process spans from initial safety validation during the cell bank and harvest stages, all the way to the final quality control at commercial batch release. Such a thorough approach ensures compliance with regulatory standards from development through to commercialization.

WuXi Biologics operates its Biosafety Testing Center with two strategically located facilities in Suzhou and Shanghai. The center provides a wide range of services, including cell bank characterization and diverse biosafety testing for various biologics products. So far, WuXi Biologics’ Biosafety Testing Center has successfully facilitated over 1,700 investigational new drug (IND) and biologics license application (BLA) submissions.

The quality system and technical competencies of the facility have not only received accolades from the EMA but have been recognized by several global regulatory authorities. The Suzhou center has successfully passed inspections by renowned bodies, including the U.S. Food and Drug Administration (FDA), and other organizations such as China National Accreditation Service for Conformity Assessment (CNAS), National Medical Products Administration (NMPA) in China, and the Therapeutic Goods Administration (TGA) in Australia, among others.

WuXi Biologics, with its extensive global reach, employs over 13,000 staff across its facilities in different countries, including the United States, Ireland, and Singapore. This workforce comprises experts and scientists dedicated to advancing the research and manufacturing of biologics. By prioritizing digital capabilities and seamless integration across the biopharmaceutical supply chain, WuXi Biologics enhances transparency, accelerates development timelines, and promotes efficiency in manufacturing processes.

With rising global awareness and emphasis on sustainability, WuXi Biologics places great value on environmentally responsible practices. The organization actively drives innovation toward providing end-to-end Green CRDMO solutions that embark on excellent Environmental, Social, and Governance (ESG) principles. By nurturing collaborative efforts with its partners, WuXi Biologics strives to create positive social and environmental impacts while ensuring responsible practices label every step of its value chain.

For anyone interested in learning more about WuXi Biologics and its comprehensive offerings, detailed information is available on its official website, ensuring an insight into its extensive capabilities in enabling the development and manufacturing of biologics to benefit patients worldwide.